BridgeBio Highlights Acoramidis Efficacy in ATTR-CM with New ESC 2026 Data
Event summary
- BridgeBio to present new acoramidis data at ESC Congress 2026, including two oral presentations and three posters on ATTR-CM.
- Data reinforces acoramidis as the first-line treatment for ATTR-CM, with near-complete (≥90%) TTR stabilization.
- Acoramidis approved as Attruby® in the U.S. and BEYONTTRA® in Europe, Japan, Switzerland, UK, and Brazil.
- Three additional posters on AI networks for earlier ATTR-CM detection presented in partnership with Yale's CarDS Lab.
- Presentations include long-term survival benefits, quality of life improvements, and AI-derived digital biomarkers.
The big picture
BridgeBio's presentation at ESC 2026 underscores its strategic focus on genetic conditions, particularly ATTR-CM. The company's emphasis on AI-driven diagnostics and long-term clinical data positions it at the forefront of precision medicine. The broader industry trend toward decentralized, patient-led digital registries and AI integration in healthcare could further enhance BridgeBio's competitive edge.
What we're watching
- Clinical Validation
- Whether the new data will solidify acoramidis' position as the first-line treatment for ATTR-CM.
- Regulatory Expansion
- The pace at which acoramidis gains approvals in additional markets beyond current regions.
- AI Integration
- How BridgeBio's AI partnerships will impact early detection and treatment of ATTR-CM.